Skip to main content
Neurology

Examining Tominersen as a Potential Treatment for Huntington Disease: The GENERATION HD2 trial

The phase 2 trial tests Roche’s investigational antisense oligonucleotide therapy tominersen in patients with early stages of Huntington disease, a disease with no FDA-approved therapies available.:

Source: Neurology Read More

Related Posts

Neurology <![CDATA[Once-Daily Alixorexton Improves Cognition, Fatigue, and Disease Severity in Phase 2 Narcolepsy Type 1 Study]]>

<![CDATA[Once-Daily Alixorexton Improves Cognition, Fatigue, and Disease Severity in Phase 2 Narcolepsy Type 1 Study]]>

April 21, 2026
Neurology <![CDATA[NMOSD Associated With Escalation to Rituximab, Elecsys NfL Test Receives European Approval, Neurology by the Numbers]]>

<![CDATA[NMOSD Associated With Escalation to Rituximab, Elecsys NfL Test Receives European Approval, Neurology by the Numbers]]>

April 20, 2026
Neurology <![CDATA[GLP-1 Receptor Agonists Show Translational Potential in Alzheimer Disease Despite Mixed Study Results]]>

<![CDATA[GLP-1 Receptor Agonists Show Translational Potential in Alzheimer Disease Despite Mixed Study Results]]>

April 20, 2026